New drug combo shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT02326974
First seen Apr 23, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests whether giving two targeted drugs (T-DM1 and pertuzumab) before surgery can eliminate all signs of cancer in women with early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the combination, and doctors will check if the tumor completely disappears by the time of surgery. The goal is to improve treatment and understand how different levels of the HER2 protein affect response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Tennessee Oncology/Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.